Verification evidence is still being completed.
PDF / print export
Captor Therapeutics
Wroclaw, Poland
- Verified lead
- Michał Walczak
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer and Chief Scientific Officer
- 2026 technical specialization
- Targeted Protein Degradation, Molecular Glues, Oncology Discovery, and Small-Molecule Platform Chemistry
- Review cycle
- May 2026
- Full address
- ul. Duńska 11, 54-427 Wrocław, Poland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Captor Therapeutics management-board disclosure.
- Editorial note
- Precision-degradation discovery node with oncology-focused degrader chemistry and translational biology depth in Wroclaw.
Targeted Protein Degradation, Molecular Glues, Oncology Discovery, and Small-Molecule Platform Chemistry
Drug-discovery quality systems, Clinical-transition programme governance
Precision-degradation discovery node with oncology-focused degrader chemistry and translational biology depth in Wroclaw.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Wroclaw, Poland
Captor Therapeutics
Targeted Protein Degradation, Molecular Glues, Oncology Discovery, and Small-Molecule Platform Chemistry · Precision-degradation discovery platform
Precision-degradation discovery node with oncology-focused degrader chemistry and translational biology depth in Wroclaw.
- Lead
- Michał Walczak (verified ↗)
- Address
- ul. Duńska 11, 54-427 Wrocław, Poland (source ↗)
- Compliance
- GLP
- Last reviewed
- 15 Mar 2026 (3mo ago)
- Scale
- Precision-degradation discovery platform
- Capabilities
- Targeted protein degradation · Small-molecule discovery · Oncology programme development
- Founded
- 2017
- Headcount
- 51-200
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Michał Walczak
Chief Executive Officer and Chief Scientific Officer
Full addressul. Duńska 11, 54-427 Wrocław, Poland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Captor Therapeutics contact page listing the Wrocław headquarters at ul. Duńska 11.
Open sourcePrecision-degradation discovery platform
Wroclaw, Poland. Targeted Protein Degradation, Molecular Glues, Oncology Discovery, and Small-Molecule Platform Chemistry. Review completed on 15 Mar 2026.
Polish and EU biotech discovery governance framework
Drug-discovery quality systems, Clinical-transition programme governance
Targeted Protein Degradation, Molecular Glues, Oncology Discovery, and Small-Molecule Platform Chemistry
Precision-degradation discovery node with oncology-focused degrader chemistry and translational biology depth in Wroclaw.
Editorial note
Captor gives the Polish cluster a precision-degradation node with current executive disclosure and a differentiated small-molecule discovery platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Targeted protein degradation
Small-molecule discovery
Oncology programme development
Preclinical translational science
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Medicinal chemistry labs
Target-validation workflows
Preclinical translational infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- VERIFIED ACTIVE 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
15 Mar 2026: Executive identity confirmed via official management disclosure.
15 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Captor Therapeutics located?
- Captor Therapeutics operates from ul. Duńska 11, 54-427 Wrocław, Poland, Wroclaw, Poland.
- Who runs Captor Therapeutics?
- Captor Therapeutics is led by Michał Walczak, Chief Executive Officer and Chief Scientific Officer. Verified 15 Mar 2026.
- What does Captor Therapeutics do?
- Precision-degradation discovery node with oncology-focused degrader chemistry and translational biology depth in Wroclaw. Core capabilities: Targeted protein degradation, Small-molecule discovery, Oncology programme development, Preclinical translational science.
Editorial context
Related technical briefs
Briefs that name Wroclaw as a covered market or city.